Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2019-07-04 Declaration of Voting R…
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Otrzymanie zawiadomienia, o którym mowa w art. 69 ustawy o ofercie publicznej - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is in Polish and discusses a notification received based on Polish public offering laws (art. 69, art. 69a, art. 87). The core content details a transaction (sale of shares) between two entities (TOTAL FIZ and TTL 1) and the resulting change (or lack thereof) in the total shareholding percentage (26.25%) held by TOTAL FIZ. This structure—reporting a change in significant share ownership thresholds—is characteristic of a Major Shareholding Notification. The final sentence states, "Treść otrzymanego zawiadomienia stanowi załącznik do niniejszego raportu" (The content of the received notification constitutes an attachment to this report), suggesting this document is the announcement of the notification, but the primary subject matter is the change in ownership percentage, which maps directly to the Major Shareholding Notification category (MRQ). Given the specific nature of reporting shareholding changes crossing thresholds, MRQ is the most precise fit over the general RNS.
2019-07-04 Polish
Informacja o decyzji o przyznaniu europejskiego patentu na wynalazek stanowiący kluczową technologię dla działania systemu PCR|ONE - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document is a short announcement (1533 characters) written in Polish by the Management Board ('Zarząd') of Scope Fluidics. It reports that a subsidiary, Curiosity Diagnostics, has received a conditional decision from the European Patent Office to grant a European patent for a specific technology related to their PCR|ONE analyzer. The text details the implications of receiving the patent (commercial monopoly) and mentions ongoing efforts to secure a patent in China, referencing a previous report (raport bieżący nr 2/2017). Since this is a specific, material announcement regarding intellectual property and regulatory/legal progress, and it is not a full report, it fits best under 'Legal Proceedings Report' (LTR) due to the focus on patent grants/litigation/IP matters, or potentially 'Regulatory Filings' (RNS) as a general regulatory update. Given the specific nature concerning a patent grant decision, LTR is a strong candidate, but since patent grants are often treated as specific regulatory/legal news, and RNS is the general fallback for non-standard regulatory news, I will evaluate the options. LTR covers lawsuits and regulatory actions. Patent grants are regulatory decisions affecting legal rights. Given the options, LTR seems slightly more specific than RNS for an update on a patent decision. However, if the focus is purely on the announcement mechanism rather than the legal outcome itself, RNS might apply. Since it details a specific legal/IP event (patent grant), LTR is chosen over the general RNS fallback, as it pertains to legal rights protection.
2019-07-02 Polish
Zakończenie czwartego etapu prac badawczo-rozwojowych nad systemem PCR|ONE - Content (PL)
Management Reports Classification · 1% confidence The document is written in Polish and details the completion of the fourth stage of R&D work on the PCR|ONE system by a subsidiary, Curiosity Diagnostics. It outlines specific technical achievements, including optimizing biochemical reactions, manufacturing injection molds for microfluidic chips, setting up a pilot filling line, constructing analyzers, and signing an agreement for pre-validation tests. This content describes significant operational and technical progress related to product development and testing, which is characteristic of an ongoing project update or a detailed management report on operational milestones, rather than a formal financial filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). Since it details management's explanation of progress and technical achievements, it aligns best with the Management Reports (MDA) category, which covers business trends and operational updates, even if the focus here is R&D rather than pure financial results.
2019-06-28 Polish
Podpisanie umowy z ALAB laboratoria sp. z o.o. przez spółkę zależną Emitenta - Content (PL)
Regulatory Filings Classification · 1% confidence The document is written in Polish and discusses a subsidiary signing an agreement ('Umowa') with ALAB laboratoria to conduct pre-validation tests for the PCR|ONE system. It details milestones, timelines (Q3 2019 - Q1 2020), and the purpose of the tests (determining optimal technical specifications). This content relates to ongoing operational developments, partnerships, and technical progress, rather than standard periodic financial reporting (10-K, IR, ER) or formal shareholder/board actions (AGM-R, DEF 14A). Since it is an announcement about a significant operational agreement and progress milestone, it fits best under a general regulatory announcement or operational update. Given the specific definitions, it is not a Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV). It is a specific operational update that doesn't perfectly match the other categories. Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a 'raport bieżący' (current report) detailing a material event that doesn't fit a more specific operational category like M&A (TAR) or Financing (CAP).
2019-06-27 Polish
Informacja dotycząca współpracy z Microfluidic ChipShop - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement in Polish, referencing previous current reports ('raport bieżący') regarding a development schedule (PCR|ONE system) and an agreement with a partner (Microfluidic ChipShop GmbH). The core information is the signing of an agreement to terminate the existing cooperation ('porozumienie o zakończeniu wynikającej z niej współpracy'). This concerns a change in business operations, project execution strategy, and contractual relationships, which falls under general corporate updates. Since it is a specific announcement about a material event (termination of a key agreement) and not a standard financial report (10-K, IR, ER), it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard announcements, or potentially a Legal/Contractual update, but RNS is the most appropriate fallback for non-standard corporate actions not covered by specific codes like M&A (TAR) or Capital (CAP). Given the context of reporting material events, RNS is the best fit.
2019-04-11 Polish
Powołanie dr Agnieszki Sulikowskiej w skład Komitetu Doradczego - Content (PL)
Board/Management Information Classification · 1% confidence The document text announces the appointment of Dr. Agnieszka Sulikowska to the Advisory Committee of Scope Fluidics S.A. The content focuses entirely on the background, qualifications, and role of a newly appointed individual within the company's advisory structure. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management (or related advisory bodies). The document is not a financial report, earnings release, or legal filing.
2019-04-09 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.